Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection
Recommended Citation
Summers BB. Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection Drugs Today (Barc) 2018; 54(4):255-268.
Document Type
Article
Publication Date
4-1-2018
Publication Title
Drugs of today (Barcelona, Spain : 1998)
Abstract
Hepatitis C virus (HCV) is a significant public health burden worldwide, owing in large part to ineffective and poorly tolerated treatments. The antivirals have evolved over time to become more effective and better tolerated with cure rates increasing from an average of 50% to a complete virologic response. This article summarizes the latest Food and Drug Administration (FDA)-approved addition to combination treatment for patients with HCV, voxilaprevir plus sofosbuvir/velpatasvir.
Medical Subject Headings
Antiviral Agents; Carbamates; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Sofosbuvir; Sulfonamides; Treatment Outcome
PubMed ID
29869647
Volume
54
Issue
4
First Page
255
Last Page
268
